Evaluation & grants
Grant recipients have the opportunity to receive funding of up to $10,000 to support the development and implementation of their proposed solution. Grant funding provided will vary based on the scale of the idea submitted.
Anyone can submit their ideas through the platform. You can submit as many ideas as you want. Feel free to collaborate, share your thoughts with others, and combine efforts.
After the Idea Phase closes, the expert panel will evaluate the ideas and create a shortlist. During this period, submitted ideas on the platform will be locked, although we encourage you to leave comments, feedback, or insights.
During this phase, up to 15 shortlisted participants will be invited to further build out their idea, adding details such as a timeline and estimated budget allocation to provide a better sense of how you will bring your idea to life.
The expert panel will review the refined ideas and evaluate them against the eligibility criteria to select the potential final grant recipients. Potential final grant recipients will then undergo a required due diligence review and will need to sign an agreement with the sponsors of this challenge before grants can be awarded.
The final selection of the ideas will be based on the following criteria. Please keep them in mind when developing your idea and giving feedback to other participants:
Human-centered: Is the idea centered around real, human experiences that demonstrate an understanding of the disease impact?
Innovative: Does the solution tackle this issue in creative new ways – big or small?
Locally focused: Does the idea have the potential to make a real difference in your local community?
Measurable: Is there a way to measure the impact of the idea on the AD community? How many people could the idea help? How significant would the impact be?
Feasible: Is the idea realistic enough to bring to life within a defined timeframe?
Our expert panel consists of a team of global AD experts and representatives from Sanofi and Regeneron, who will review and evaluate the ideas:
Developer of ‘Eczema Tracker’, a free app-based solution to help patients track and manage symptoms, and mother of a child living with AD.
Director of Communication for the Association of People Affected by Atopic Dermatitis in Spain and living with severe AD herself.
Programs Director at the International Alliance of Dermatology Patient Organizations, also known as GlobalSkin.
MAT-GLB-2202287 V1.0 | June 2022